Inhibikase Therapeutics (IKT) Corporate presentation summary

PAH market and unmet need

• PAH is progressive and life-threatening, with ~30% 5-year mortality despite specialist-directed vasodilator treatment.

• The presentation estimates 50,000 people with PAH in the US and 26,000 in EU5; average US monthly healthcare costs are $6,850–$15,650.

• The 2025 PAH market is estimated at $8.3B; antiproliferatives are projected to drive growth, with the segment potentially reaching $8B by 2034 under stated pricing and regimen assumptions.

IKT-001 rationale and evidence

• IKT-001 is an oral, once-daily imatinib prodrug designed to retain efficacy while reducing GI exposure; preclinical work showed ~20x less kinase inhibition and 2.5x better GI tolerability than imatinib in non-human primates.

• In preclinical studies, IKT-001 remained intact in the GI tract and was 18x less potent at c-kit than imatinib; it showed no effect on gastric emptying.

• In the Phase 3 IMPRES trial, imatinib achieved a placebo-adjusted 32m 6MWD improvement and 32% PVR reduction at Week 24; patients on 400mg for >50% of treatment had a 45m placebo-adjusted 6MWD improvement.

• IKT-001 dose-dependently improved pulmonary hemodynamics and reversed disease features in a preclinical PAH model; combination treatment with an activin signaling inhibitor showed additive hemodynamic improvement.

Phase 3 program and design

• IMPROVE-PAH is a global Phase 3 program: Part A enrolls 140 patients with PVR as the primary endpoint; Part B enrolls 346 with 6MWD as the primary endpoint.

• The protocol uses 12-week titration to maximum tolerated dose, with step-down dosing; design features also include edema-event adjudication, anticoagulant exclusion and evening dosing.

• Enrollment is ongoing across 28 countries, with 79 of 180 planned sites active; Part A first-patient enrollment began in Q1 2026.

• Planned milestones include interim Part A safety in 1H 2027, Part A PVR data in mid-2028 and Part B 6MWD topline data in mid-2029.